Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-05-09
DOI
10.3389/fonc.2017.00072
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 996PCETUXIMAB RELATIVE DOSE INTENSITY (RDI) IN RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): FIRST OBSERVATIONAL PROSPECTIVE STUDY IN UNSELECTED PATIENTS (DIRECT TRIAL)
- (2017) J. Guigay et al. ANNALS OF ONCOLOGY
- A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)
- (2016) M.J. Ratcliffe et al. ANNALS OF ONCOLOGY
- Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141
- (2016) Maura L. Gillison et al. CANCER RESEARCH
- Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
- (2016) S. Trivedi et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response inKRASwild-type metastatic colorectal cancer patients
- (2016) Cristiana Lo Nigro World Journal of Gastrointestinal Oncology
- Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
- (2016) John Pradeep Veluchamy et al. PLoS One
- Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
- (2015) J. Guigay et al. ANNALS OF ONCOLOGY
- Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
- (2015) L. Apetoh et al. ANNALS OF ONCOLOGY
- Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma
- (2015) Vandana Singh Kushwaha et al. CANCER BIOLOGY & THERAPY
- DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis
- (2015) Jonathan F. Goodwin et al. CANCER CELL
- Abstract 1327: Variable impact of chemotherapy +/- cetuximab on immune modulation in a prospective cohort of 163 cancer patients:
- (2015) Cristiana Lo Nigro et al. CANCER RESEARCH
- 2865 Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): A retrospective analysis
- (2015) M. Siano et al. EUROPEAN JOURNAL OF CANCER
- The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors
- (2015) Zev A Wainberg et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
- (2015) Danny Rischin et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Immunotherapy for Head and Neck Squamous Cell Carcinoma
- (2015) David W. Schoppy et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1
- (2015) Amer Assal et al. Immunotherapy
- EGFR inhibition for recurrent or metastatic HNSCC
- (2015) Athanassios Argiris LANCET ONCOLOGY
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck
- (2015) Daniel R. Simpson et al. ORAL ONCOLOGY
- PD-036: Association of HPV/p16 status with efficacy and safety in pts with OPC in the phase 3 RT/cetuximab registration trial
- (2015) J.A. Bonner et al. RADIOTHERAPY AND ONCOLOGY
- The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival
- (2015) Julie Delyon et al. SEMINARS IN ONCOLOGY
- Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations
- (2015) Kathryn Baksh et al. SEMINARS IN ONCOLOGY
- Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab
- (2015) Rodney J. Taylor et al. Cancer Immunology Research
- A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
- (2015) Walter Urba et al. Journal for ImmunoTherapy of Cancer
- A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
- (2015) Jan Baughman et al. Journal for ImmunoTherapy of Cancer
- Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
- (2015) Robert L Ferris et al. Journal for ImmunoTherapy of Cancer
- A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†
- (2014) T. Y. Seiwert et al. ANNALS OF ONCOLOGY
- An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
- (2014) Vassiliki Saloura et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
- (2014) Dan P. Zandberg et al. ORAL ONCOLOGY
- Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution
- (2014) Ramon Andrade de Mello et al. PLoS One
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
- (2013) Bernard Escudier et al. DRUGS
- Outcome of patients treated with palliative weekly Paclitaxel plus Cetuximab in recurrent head and neck cancer after failure of platinum-based therapy
- (2013) Aaron E. Sosa et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
- (2013) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
- (2013) Jan B Vermorken et al. LANCET ONCOLOGY
- Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie
- (2013) M. Knoedler et al. ONCOLOGY
- Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes
- (2013) Frédéric Peyrade et al. ORAL ONCOLOGY
- Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma
- (2012) Julien Péron et al. ANTI-CANCER DRUGS
- Current Treatment Options for Metastatic Head and Neck Cancer
- (2012) Katharine A. R. Price et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer
- (2012) Paolo Bossi et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
- (2012) Mark Agulnik MEDICAL ONCOLOGY
- Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients
- (2012) Begoña Jiménez et al. ORAL ONCOLOGY
- Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
- (2011) R. Hitt et al. ANNALS OF ONCOLOGY
- Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
- (2011) Jean-Pascal Machiels et al. LANCET ONCOLOGY
- Optimal treatment for recurrent/metastatic head and neck cancer
- (2010) J. B. Vermorken et al. ANNALS OF ONCOLOGY
- Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) V. Gregoire et al. ANNALS OF ONCOLOGY
- MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer
- (2010) Xiaofan Zhang et al. CARCINOGENESIS
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
- (2010) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer
- (2010) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel and irinotecan in recurrent or metastatic head and neck cancer
- (2009) Athanassios Argiris et al. CANCER
- Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck
- (2009) Byoung Chul Cho et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial
- (2009) Fernando Rivera et al. Expert Review of Anticancer Therapy
- Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies
- (2008) Jan. B. Vermorken et al. CANCER
- Head and neck cancer
- (2008) Athanassios Argiris et al. LANCET
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now